COMPANY

EpiVario Inc.

HQ: Philadelphia, PA source · epivario.com ↗ · Mid-Atlantic

Keywords: psychiatry post-traumatic stress disorder small molecule

Location: Philadelphia, PA · source · Oct 15, 2026

Profile checked Oct 10, 2026

NIH awards 3

Annual award amounts. Total $831K.

Sep 17, 2024 NIH award 1R43DA058603-01A1 FY2024: $275,253 awarded for that fiscal year; activity R43 (SBIR); PI KIM, THOMAS; recipient as written: EPIVARIO, LLC, PHILADELPHIA, PA. Developing a novel epigenetic regulator as a trea source ↗
May 28, 2024 NIH award 1R43DA060726-01 FY2024: $295,325 awarded for that fiscal year; activity R43 (SBIR); PI KIM, THOMAS; recipient as written: EPIVARIO, LLC, PHILADELPHIA, PA. Developing a novel epigenetic regulator as a treatm source ↗
Aug 23, 2022 NIH award 1R41AA030516-01 FY2022: $259,971 awarded for that fiscal year; activity R41 (STTR); PI CHABOUB, LESLEY S.; recipient as written: EPIVARIO, LLC, PHILADELPHIA, PA. ACSS2 inhibition in treating Alcohol Abuse source ↗

SEC Form D raise Raised $185K in debt securities (Form D filed Oct 13, 2026). SEC Form D 0001753351-26-000001 (Oct 13, 2026)
Evidence (1 event)
- Oct 13, 2026 · SEC Form D 0001753351-26-000001
  Name of Issuer: EpiVario Inc.; CIK: 1753351; Address: Philadelphia, PA; Submission type: D; Filing date: 2026-10-13; Industry Group: Pharmaceuticals; Date of First Sale: 2026-09-25; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 500000; Total Amount Sold: 185000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals